MorphoSys Net Income vs Income Before Tax Analysis
MOR Stock | USD 19.00 0.34 1.76% |
MorphoSys financial indicator trend analysis is infinitely more than just investigating MorphoSys AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MorphoSys AG ADR is a good investment. Please check the relationship between MorphoSys Net Income and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
Net Income vs Income Before Tax
Net Income vs Income Before Tax Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MorphoSys AG ADR Net Income account and Income Before Tax. At this time, the significance of the direction appears to have almost identical trend.
The correlation between MorphoSys' Net Income and Income Before Tax is 0.94. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of MorphoSys AG ADR, assuming nothing else is changed. The correlation between historical values of MorphoSys' Net Income and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of MorphoSys AG ADR are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Net Income i.e., MorphoSys' Net Income and Income Before Tax go up and down completely randomly.
Correlation Coefficient | 0.94 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in MorphoSys AG ADR financial statement analysis. It represents the amount of money remaining after all of MorphoSys AG ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on MorphoSys income statement and is an important metric when analyzing MorphoSys AG ADR profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most indicators from MorphoSys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MorphoSys AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. At this time, MorphoSys' Selling General Administrative is relatively stable compared to the past year. As of 05/19/2024, Sales General And Administrative To Revenue is likely to grow to 0.38, though Tax Provision is likely to grow to (1.1 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 181.5M | 116.5M | 109.9M | 115.4M | Depreciation And Amortization | 98.4M | 10.5M | 10.5M | 10.4M |
MorphoSys fundamental ratios Correlations
Click cells to compare fundamentals
MorphoSys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MorphoSys fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Other Current Liab | 46.8M | 146.9M | 206.9M | 230.2M | 202.4M | 212.5M | |
Total Current Liabilities | 61.6M | 200.5M | 284.5M | 278.3M | 264.3M | 277.5M | |
Total Stockholder Equity | 394.7M | 621.3M | 244.9M | 157.4M | 49.0M | 46.6M | |
Property Plant And Equipment Net | 4.7M | 50.7M | 49.6M | 51.0M | 15.0M | 11.8M | |
Net Debt | (1.7M) | 208.4M | 202.5M | (62.9M) | 477.4M | 501.3M | |
Retained Earnings | (255.8M) | (157.9M) | (672.3M) | (823.4M) | (1.0B) | (962.5M) | |
Accounts Payable | 10.7M | 47.6M | 73.8M | 38.6M | 28.4M | 14.7M | |
Cash | 44.3M | 109.8M | 123.2M | 402.4M | 158.5M | 166.4M | |
Non Current Assets Total | 192.7M | 452.7M | 1.4B | 1.3B | 1.2B | 1.3B | |
Non Currrent Assets Other | 44.1M | 1.6M | 4.1M | 8.7M | 1.2M | 1.2M | |
Cash And Short Term Investments | 272.5M | 1.1B | 993.7M | 907.2M | 682.8M | 716.9M | |
Common Stock Total Equity | 29.4M | 31.8M | 32.0M | 32.9M | 37.8M | 34.8M | |
Common Stock Shares Outstanding | 31.6M | 132.7M | 133.6M | 136.6M | 137.3M | 103.8M | |
Liabilities And Stockholders Equity | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Non Current Liabilities Total | 40.2M | 837.7M | 2.0B | 2.0B | 1.7B | 1.8B | |
Other Current Assets | (40.3K) | 10.0M | 15.9M | (367.0) | 24.0 | 22.8 | |
Other Stockholder Equity | 619.8M | 744.1M | 830.2M | 831.3M | 936.1M | 982.9M | |
Total Liab | 101.7M | 1.0B | 2.3B | 2.2B | 2.0B | 2.1B | |
Property Plant And Equipment Gross | 20.8M | 50.7M | 69.9M | 71.5M | 37.7M | 39.6M | |
Total Current Assets | 303.7M | 1.2B | 1.1B | 1.1B | 814.0M | 854.7M | |
Intangible Assets | 41.1M | 69.4M | 838.3M | 886.6M | 844.1M | 886.3M | |
Common Stock | 31.8M | 32.0M | 32.9M | 34.2M | 37.7M | 35.4M | |
Other Assets | 1.1M | 134.4M | 199.8M | 8.7M | 10.0M | 9.5M | |
Net Receivables | 20.3M | 89.8M | 85.8M | 112.4M | 42.7M | 83.8M | |
Inventory | 288.2K | 10.0M | 20.8M | 24.3M | 62.1M | 65.2M | |
Short Long Term Debt Total | 42.6M | 318.2M | 325.8M | 339.5M | 635.9M | 667.7M | |
Good Will | 3.7M | 1.6M | 335.6M | 356.2M | 342.3M | 359.4M | |
Accumulated Other Comprehensive Income | (1.3M) | 2.2M | 52.8M | 115.3M | 88.4M | 92.9M | |
Current Deferred Revenue | 1.6M | 2.5M | 223.9K | 19.4M | 17.5M | 18.4M | |
Short Term Investments | 228.2M | 980.5M | 870.4M | 504.8M | 524.3M | 372.9M | |
Short Term Debt | 2.5M | 3.5M | 3.7M | 9.6M | 14.1M | 14.2M | |
Other Liab | 138.1K | 523.0M | 1.7B | 1.6B | 1.9B | 2.0B | |
Net Tangible Assets | 349.9M | 550.3M | (929.0M) | (1.1B) | (976.9M) | (928.0M) | |
Long Term Debt | 0.0 | 272.8M | 282.8M | 291.6M | 613.1M | 643.7M | |
Long Term Investments | 96.0M | 99.0M | 196.6M | 5.4M | 3.6M | 3.4M | |
Property Plant Equipment | 47.8M | 50.7M | 49.6M | 51.0M | 58.6M | 61.6M | |
Capital Lease Obligations | 42.6M | 45.0M | 42.6M | 45.8M | 12.4M | 23.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for MorphoSys Stock analysis
When running MorphoSys' price analysis, check to measure MorphoSys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MorphoSys is operating at the current time. Most of MorphoSys' value examination focuses on studying past and present price action to predict the probability of MorphoSys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MorphoSys' price. Additionally, you may evaluate how the addition of MorphoSys to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is MorphoSys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MorphoSys. If investors know MorphoSys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MorphoSys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share (1.50) | Revenue Per Share 1.7163 | Quarterly Revenue Growth 0.131 | Return On Assets (0.14) |
The market value of MorphoSys AG ADR is measured differently than its book value, which is the value of MorphoSys that is recorded on the company's balance sheet. Investors also form their own opinion of MorphoSys' value that differs from its market value or its book value, called intrinsic value, which is MorphoSys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MorphoSys' market value can be influenced by many factors that don't directly affect MorphoSys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MorphoSys' value and its price as these two are different measures arrived at by different means. Investors typically determine if MorphoSys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MorphoSys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.